CD8A and neoplasm: This pathway enhances tumor immunogenicity by upregulating MHC-I expression and tumor antigen presentation required for CD8+ T cell recognition, while concurrently promoting B cell antibody production and amplifying the functionality of dendritic cell (DC) and T cell populations (16, 17).